Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkers

Key clinical point: In lung cancer patients receiving immune checkpoint inhibitor therapy, major adverse cardiac events occurred earlier than in patients receiving other types of lung cancer treatment, and occurred more frequently in patients with elevated biomarkers.

Major finding: MACE occurred at a median time to event of 40 days in the checkpoint inhibitor group,versus 118 days in the non–checkpoint inhibitor–treated patients. Risk of MACE with checkpoint inhibitor treatment was increased in patients with elevated troponin (HR, 2.48; P = .017) or elevated BNP (HR, 5.77; P less than .001).

Study details: A retrospective cohort study that included 252 patients with lung cancer treated at one of seven cancer center sites.

Disclosures: No disclosures were reported.

Citation:

Chitturi KR et al. 2019 HFSA 2019, Abstract 127.